Stockscreener 앱 받기
121.10
0.36%
0.43
시간 외 거래:
121.10
전일 마감가:
$120.67
열려 있는:
$120.34
하루 거래량:
6.53M
Relative Volume:
0.97
시가총액:
$150.25B
수익:
$29.05B
순이익/손실:
$8.11B
주가수익비율:
18.76
EPS:
6.4563
순현금흐름:
$9.16B
1주 성능:
-0.41%
1개월 성능:
+1.46%
6개월 성능:
+6.94%
1년 성능:
+35.85%
1일 변동 폭
$119.33
$122.76
1주일 범위
$116.88
$125.11
52주 변동 폭
$88.57
$128.70
길리어드 사이언스 Stock (GILD) Company Profile
명칭
Gilead Sciences Inc
전화
(650) 574-3000
주소
333 LAKESIDE DR, FOSTER CITY, CA
GILD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
121.10 | 149.71B | 29.05B | 8.11B | 9.16B | 6.4563 |
|
LLY
Lilly Eli Co
|
1,063.56 | 971.27B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
204.39 | 495.71B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
220.08 | 396.12B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
MRK
Merck Co Inc
|
110.53 | 275.48B | 63.90B | 19.05B | 13.05B | 7.5596 |
|
NVS
Novartis Ag Adr
|
141.54 | 271.43B | 54.45B | 14.42B | 17.15B | 7.333 |
길리어드 사이언스 Stock (GILD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-07 | 재개 | UBS | Buy |
| 2025-11-24 | 재개 | Truist | Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-08-19 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | 업그레이드 | Truist | Hold → Buy |
| 2025-07-25 | 업그레이드 | Needham | Hold → Buy |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-03-04 | 재확인 | Oppenheimer | Outperform |
| 2025-02-18 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-02-13 | 업그레이드 | DZ Bank | Hold → Buy |
| 2025-01-10 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 재개 | BofA Securities | Buy |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-14 | 개시 | Citigroup | Buy |
| 2024-11-08 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2024-10-21 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | 개시 | Bernstein | Outperform |
| 2024-10-07 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | 재확인 | Maxim Group | Buy |
| 2024-04-24 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2024-02-22 | 다운그레이드 | Truist | Buy → Hold |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-09-08 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-09-06 | 개시 | HSBC Securities | Reduce |
| 2023-07-24 | 재확인 | Barclays | Equal Weight |
| 2023-05-16 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | 재개 | Piper Sandler | Overweight |
| 2023-01-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | 재개 | BofA Securities | Neutral |
| 2022-12-09 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2022-10-31 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2022-10-28 | 재확인 | BMO Capital Markets | Market Perform |
| 2022-10-28 | 재확인 | Cowen | Outperform |
| 2022-10-28 | 재확인 | JP Morgan | Overweight |
| 2022-10-28 | 재확인 | Jefferies | Buy |
| 2022-10-28 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-10-28 | 업그레이드 | Truist | Hold → Buy |
| 2022-10-28 | 재확인 | Wells Fargo | Equal Weight |
| 2022-10-04 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-02-28 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | 재확인 | BMO Capital Markets | Outperform |
| 2022-02-02 | 재확인 | BofA Securities | Neutral |
| 2022-02-02 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-02-02 | 재확인 | Truist | Hold |
| 2022-02-02 | 재확인 | Wells Fargo | Equal Weight |
| 2022-01-28 | 업그레이드 | Argus | Hold → Buy |
| 2022-01-06 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-12-06 | 개시 | Goldman | Neutral |
| 2021-11-19 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | 재개 | Piper Sandler | Neutral |
| 2021-10-20 | 재개 | Cowen | Outperform |
| 2021-07-30 | 재확인 | BMO Capital Markets | Market Perform |
| 2021-07-30 | 재확인 | RBC Capital Mkts | Outperform |
| 2021-04-01 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | 업그레이드 | Redburn | Neutral → Buy |
| 2021-01-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-11-03 | 재개 | Morgan Stanley | Equal-Weight |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-09-30 | 재개 | Jefferies | Buy |
| 2020-09-15 | 업그레이드 | Maxim Group | Hold → Buy |
| 2020-07-31 | 재확인 | Credit Suisse | Neutral |
| 2020-07-31 | 재확인 | Morgan Stanley | Equal-Weight |
| 2020-07-31 | 재확인 | Piper Sandler | Overweight |
| 2020-07-31 | 재확인 | RBC Capital Mkts | Outperform |
| 2020-07-31 | 재확인 | SunTrust | Hold |
| 2020-07-31 | 재확인 | Wells Fargo | Equal Weight |
| 2020-07-20 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | 업그레이드 | SunTrust | Sell → Hold |
| 2020-05-01 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-05-01 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | 다운그레이드 | SunTrust | Hold → Sell |
| 2020-04-27 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-04-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | 다운그레이드 | CFRA | Hold → Sell |
모두보기
길리어드 사이언스 주식(GILD)의 최신 뉴스
Is Gilead Sciences (GILD) Pricing Reflecting Recent 38.5% One Year Share Return? - Yahoo Finance UK
Philip James Wealth Mangement LLC Lowers Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead price target raised to $154 from $144 at BofA - Yahoo Finance
Oregon Public Employees Retirement Fund Acquires 34,235 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
BofA Securities raises Gilead Sciences stock price target to $154 on HIV franchise strength - Investing.com
Gilead Sciences, Inc. $GILD Position Lessened by Capital Investment Advisors LLC - MarketBeat
Will Gilead Sciences Inc. stock attract ESG investorsJuly 2025 Technicals & Real-Time Buy Signal Notifications - ulpravda.ru
Gilead Names Wettan Executive Vice President - BioXconomy
Gilead (GILD) Recalls Veklury Due to Contaminant Concerns - GuruFocus
What is the fair value of Gilead Sciences Inc. stock now2025 Top Gainers & Risk Controlled Stock Alerts - ulpravda.ru
Gilead presents positive data on liver fibrosis treatments - The Pharma Letter
The Escalator: Argenx, Gilead Sciences, Bristol Myers Squibb and more - Medical Marketing and Media
Gilead Sciences posts falling sales and profits, as CEO announces departure - The Pharma Letter
Gilead Sciences, Inc. $GILD Holdings Decreased by Commonwealth Equity Services LLC - MarketBeat
Today's Analyst Action: Citigroup Raises Gilead Sciences (GILD) Price Target | GILD Stock News - GuruFocus
Citigroup Boosts Gilead Sciences (NASDAQ:GILD) Price Target to $140.00 - MarketBeat
GSK/Ionis Partnered Investigational Drug Shows Strong Results In Large Hepatitis B Studies - Benzinga
UBS Raises Gilead Sciences (GILD) Price Target to $145 and Upgra - GuruFocus
Gilead Sciences (NASDAQ:GILD) Given Buy Rating at UBS Group - MarketBeat
Assessing Gilead Sciences (GILD) Valuation After Recent Share Price Momentum - Yahoo Finance
UBS raises Gilead Sciences stock price target to $145 on HIV drug outlook - Investing.com India
Gilead Sciences (NASDAQ:GILD) Nasdaq 100 Index Biopharma Scale - Kalkine Media
Key facts: Citi names Gilead Sciences a top biopharma pick; margin concerns rise - TradingView — Track All Markets
Assessing Gilead Sciences (GILD) Valuation After Mixed Near Term Returns And 9.4% Undervaluation Estimate - simplywall.st
Gilead to buy Repare Thera’s cancer candidate for up to $30M - MSN
Gilead Sciences (GILD) Stock Outlook: Mizuho Lifts Target Amid Stronger Biktarvy Timeline - MSN
Gilead Keeps Dealing With $300M OncoNano Drug Delivery Cancer Pact - BioSpace
OncoNano Medicine partners with Gilead to test drug delivery tech - Investing.com
OncoNano Medicine partners with Gilead to test drug delivery tech By Investing.com - Investing.com Canada
OncoNano Medicine Announces Research Collaboration with Gilead to Apply ON-BOARD™ Delivery Technology to Gilead’s Drug Candidate - Business Wire
Robeco Institutional Asset Management B.V. Purchases 59,295 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
GILD Stock Price, Forecast & Analysis | GILEAD SCIENCES INC (NASDAQ:GILD) - Chartmill
Gilead Sciences (GILD): Buy, Sell, or Hold Post Q3 Earnings? - Yahoo Finance
Gilead Sciences (GILD) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance
Repare Therapeutics Sells RP-3467 Cancer Program Assets to Gilead for Up to $30 Million - TipRanks
11,480 Shares in Gilead Sciences, Inc. $GILD Bought by TriaGen Wealth Management LLC - MarketBeat
Railway Pension Investments Ltd Purchases 42,200 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
The Truth About Gilead Sciences Inc (GILD): Hidden Giant or Boomer Stock Trap? - AD HOC NEWS
Gateway Investment Advisers LLC Raises Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
SteelPeak Wealth LLC Sells 94,279 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Purchased by Asset Management One Co. Ltd. - MarketBeat
Verity & Verity LLC Has $30.05 Million Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Stock Position Lifted by Allspring Global Investments Holdings LLC - MarketBeat
Gilead Sciences (NASDAQ:GILD) Upgraded to "Strong-Buy" at Wall Street Zen - MarketBeat
Former Gilead exec who oversaw $20B in drug sales takes global role at autoimmune disease company - The Business Journals
AbbVie, Gilead gift themselves clinical-stage cancer drugs via licensing deals - Fierce Biotech
Miracle Mile Advisors LLC Buys 25,117 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
CapWealth Advisors LLC Has $27.04 Million Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Bank Pictet & Cie Europe AG Boosts Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Here's How Much $1000 Invested In Gilead Sciences 15 Years Ago Would Be Worth Today - Sahm
Gilead Sciences Q3 EPS Forecast Raised by Zacks Research - MarketBeat
길리어드 사이언스 (GILD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.75%
1.21%
자본화:
|
볼륨(24시간):